Zoetis Inc. logo

Zoetis Inc.

ZTS

NYSEHealthcareDrug Manufacturers - Specialty & Generic

前收盘价

US$77.74

+US$2.72 · +3.63%

8月21日 15:59 ET

盘前

US$78.23

+US$0.49 · +0.63%

8月24日 4:52 ET

ZTS公司概览

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

GoAI评分

Buy

Favorable setup — positive multi-factor alignment

估值

96

Deep Value

动量

25

Weakening

情绪

66

Bullish

风险韧性

57

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考,并非投资建议。

公司概况

公司网站

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

行业
Drug Manufacturers - Specialty & Generic
部门
Healthcare
总部
US
首席执行官
Kristin C. Peck
上市以来
2013年2月1日
雇员
14,500

市场位置

日内区间

当前US$77.74,

52周区间

当前US$77.74,

开盘价
US$75.29
前收盘价
US$75.02
成交量
439.22万
0.63× 平均值
平均成交量
698.57万
日均成交量
市值
325.91亿 USD
贝塔
0.73
市场参考 1
50天平均值
US$76.0074
高于平均水平+2.28%
200天平均值
US$105.57
低于平均水平-26.36%

财务数据

财务快照

最近十二个月

估值与收益率

企业价值
629.75亿 USD
EV/EBITDA
15.48×
盈利收益率
4.79%
自由现金流收益率
4.09%

盈利能力和效率

净资产收益率
80.25%
资产收益率
17.28%
投入资本回报率
21.54%

财务健康

流动比率
3.03×
奥特曼 Z 分数
4.74
皮奥特罗斯基 F 分数
7 共 9 个

财报历史与展望

最新财年每股收益
6.02
2025财年 · 同比+10.05%
最新财年收入
94.67亿 USD
2025财年 · 同比+2.28%
下一财年每股收益共识
6.29
2026财年 · 10位分析师
下一财年收入共识
93.15亿 USD
2026财年 · 11位分析师

年度每股收益趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期
年度每股收益趋势8.677.075.473.8721财年22财年23财年24财年25财年26财年27财年28财年

年度营收趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期
年度营收趋势114.07亿100.87亿87.66亿74.46亿21财年22财年23财年24财年25财年26财年27财年28财年

ZTS同业公司

继续GoAI的研究

在 GoAI 中研究ZTS

research.disclaimer